linjc16/ctgov huggingface dataset:
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety/tolerability, pharmacokinetics, and efficacy of GFS101A in combination with Toripalimab in patients with advanced solid tumors.

Official Title
-----------------
A Multicenter, Open-label, Phase I/Ⅱ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFS101A in Combination With Toripalimab Treating Patients With Advanced Solid Tumors

Conditions
-----------------
Solid Tumor

Intervention / Treatment
-----------------
* Drug: GFS101A
* Drug: Toripalimab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Voluntarily participate in this clinical trial, and are willing to sign informed consent forms. Male or female aged from 18-75 years old (inclusive). Diagnosed with histologically or cytologically confirmed advanced solid tumors. Evaluable lesions defined by RECIST v1.1. Eastern Cooperative Oncology Group performance status of 0 to 1. Subjects or their legal representatives are able to communicate well with Investigators and are willing to comply with the protocol and complete the study. Exclusion Criteria: With clinically significant cardiac diseases With clinically significant digestive disorders. Other severe disease. Pregnant or lactating women. Other unfavorable situations for subjects to participate in the study judged by Investigators.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: GFS101A+Toripalimab<br>Patient will be administrated with GFS101A IV in combination with Toripalimab IV. The duration of the treatment cycle is defined as 21 days. | Drug: GFS101A<br>* GFS101A will be administrated intravenously Q3W.<br>Drug: Toripalimab<br>* Toripalimab with fixed dose of 240 mg Q3W administered intravenously.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Phase I：Incidence of dose limiting toxicity (DLT) events |  | 21days | 
| Phase II: Overall response rate (ORR) per RECIST 1.1 |  | approximately 12 months after first dose |
Registry of Etanercept Use in Patients With Rheumatoid Arthritis in Clinical Practice in Taiwan

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to develop a registry with safety and efficacy data on the use of etanercept in clinical practice in Taiwan.

Official Title
-----------------
A Registry Study to Describe the Implications of Therapeutic Management of Etanercept in Patients With Rheumatoid Arthritis

Conditions
-----------------
Rheumatoid Arthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Main Inclusion Criteria: 1) Male or female patients aged > 20 years; 2) Patients who have already been selected and approved under the Taiwan National Health Insurance Program to receive 24 weeks of etanercept for rheumatoid arthritis. Main Exclusion Criteria: Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Non-intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety: Proportion of patients discontinued from etanercept as a result of an adverse event by Week 24, laboratory exam findings, incidence of adverse events, and vital signs and physical exam findings. Efficacy: Disease Activity Score 28 at week 20. |  | 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Global health assessment; Erythrocyte sedimentation rate; Number of swollen or tender joints; C-reactive protein; Proportion of patients having worsened DAS 28 and components of DAS 28,CRP than baseline; Etanercept approval-lag time. |  | 24 weeks |
Availability Study of ACTH to Treat Children SRNS/SDNS

Study Overview
=================
Brief Summary
-----------------
Primary nephrotic syndrome(NS) is a common children renal disease.About 20% primary nephrotic syndrome are steroid-dependent and steroid-resistant.Low serum cortisol is one of the main relapse reasons.Adrenocorticotropic hormone(ACTH)-induced steroidogenesis improve serum cortisol and also direct melanocortin receptors(MCRs) mediated protective effect on kidney cells. To investigate the efficacy and safety of ACTH to treat NS, total 42 children steroid resistant or steroid dependent NS is enrolling in this multicenter, prospective case series of prescription based treatment with ACTH for NS.

Detailed Description
-----------------
Primary nephrotic syndrome(NS) is a common children renal disease.About 20% primary nephrotic syndrome are steroid-dependent and steroid-resistant.Low serum cortisol is one of the main relapse reasons.Adrenocorticotropic hormone(ACTH) can stimulates the adrenal cortex and its production of corticosteroids.ACTH also direct melanocortin receptors(MCRs) mediated protective effect on kidney cells. To investigate the efficacy and safety of ACTH to treat NS, total 42 children steroid resistant or steroid dependent NS is enrolling in this multicenter, prospective case series of prescription based treatment with ACTH for NS.

Official Title
-----------------
Availability and Safety Study of ACTH to Treat Children SRNS/SDNS

Conditions
-----------------
Proteinuria

Intervention / Treatment
-----------------
* Drug: ACTH


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age:3-12 years old primary nephrotic syndrome SRNS or SDNS Minor lesion or minimal change disease Signed informed consent Exclusion Criteria: Second nephrotic syndrome allergic to ACTH Refuse to signed informed consent have had ACTH treatment serious complication

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ACTH(+)<br>routine treatment + ACTH | Drug: ACTH<br>* routine treatment plus ACTH 0.4 Unit/kg/day (Maximum 25Unit) for three consecutive days every 4 weeks<br>* Other names: adrenocorticotropic hormone;|
| No Intervention: ACTH(-)<br>routine treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 24-hour proteinuria excretion |  | 1.5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| times of relapse |  | 1.5 years |
A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients

Study Overview
=================
Brief Summary
-----------------
This study will be looking at the safety and added benefit of using the Indocyanine green dye (ICG) during surgery.

Official Title
-----------------
Indocyanine Green Lymphangiography as a Tool for Improving Lymphadenectomy in Gastric Cancer

Conditions
-----------------
Gastric Cancer

Intervention / Treatment
-----------------
* Drug: Indocyanine green


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients ≥ 18 and ≤ 75 years of age. Primary gastric adenocarcinoma of any histological subtype confirmed pathologically by endoscopic biopsy. Clinical stage tumor T1-4a (cT1-4a), N -/+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition. No distant metastasis, no direct invasion of adjacent organs such as pancreas and spleen in preoperative exams. American Society of Anesthesiology score (ASA) class I, II, or III. Written informed consent. Exclusion Criteria: Patients ≤ 18 and ≥ 75 years of age. History of previous upper abdominal surgery (except laparoscopic cholecystectomy). History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection. History of allergy to iodine agents. History of other malignant disease within past five years. Emergency surgery due to complication caused by gastric cancer, such as bleeding obstruction or perforation. Patients intraoperatively/postoperatively confirmed as T4b. Patients intraoperatively confirmed as unable to complete D2 lymph node dissection or R0 dissection.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Intervention<br>Injection of Indocyamine Green. | Drug: Indocyanine green<br>* A one time injection of IDC prior to the day of scheduled surgery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive ICG fluorescence lymph nodes | Total number of lymph nodes removed after surgery that are positive for ICG fluorescence | Approximately 30-90 days after surgery | 
| Disease positive lymph nodes | Number of ICG positive lymph nodes that are also positive for disease | Approximately 30-90 days after surgery | 
| Number of lymph nodes removed for each lymphatic station of gastrectomy | Total number of lymph nodes removed for each lymphatic station of gastrectomy with NIR+ICG vs gastrectomy without NIR+ICG | Approximately 30-90 days after surgery |
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.

Detailed Description
-----------------
This study evaluates the use of Targretin capsules (bexarotene) in combination with Cisplatin and Vinorelbine for the treatment of metastatic non-small cell lung cancer in patients who have not yet received chemotherapy for their lung cancer. Every patient receives a platinum-containing chemotherapy every four weeks for at least four chemotherapy cycles (approximately four months). Half of the patients are randomly assigned to receive Targretin capsules once daily in addition to the chemotherapy. The other half is randomized to receive a standard platinum-containing chemotherapy without Targretin capsules.

Official Title
-----------------
Randomized Phase III Trial Comparing Targretin Capsules/Cisplatin/Vinorelbine Versus Cisplatin/Vinorelbine in Chemotherapy-Naive Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Conditions
-----------------
Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: bexarotene


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients must have: Pathologic (histologic or cytologic) confirmation of NSCLC Stage IIIB with malignant pleural effusion or Stage IV disease At least one measurable or evaluable NSCLC lesion that has not been previously irradiated unless radiation therapy was more than three weeks prior to entry in the study and the lesion has been shown to have progressed subsequent to the radiation therapy ECOG performance status 0 or 1 Adequate organ system function Fasting serum triglycerides that are within the age-adjusted normal range (or normalized with appropriate intervention such as antilipid therapy prior to the initiation of Targretin capsule therapy). Patients must be able to complete at least four cycles of combination chemotherapy (i.e., approximately four months) Patients must not have had: Brain metastasis Prior chemotherapy for NSCLC Prior platinum-based chemotherapy for any indication
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: bexarotene|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NSCLC, Targretin, Retinoid, Bexarotene
Ultrasound Evaluation of Cystic Lesions in the Knee:In Comparison to Magnetic Resonance Imaging

Study Overview
=================
Brief Summary
-----------------
Benign cysts and cystic-appearing lesions in and around the knee are common and differentiation between them through the history, symptoms and clinical examination is difficult due to the presence of common findings such as pain, edema, and palpable mass. The clinical presentation depends on the location, size of the lesion and its relation with the surrounding structures.

Detailed Description
-----------------
The Benign knee cysts can be subdivided into four major categories as following:1- synovial cysts, 2- popliteal (Baker's) cyst, 3- ganglion cysts, 4- meniscal cysts. Whereas, The cyst-like lesions can be sub-classified into the following:1- normal knee bursae, 2- normal knee recesses, 3- miscellaneous cyst-like lesions as aneurysms, hematomas, seromas and abscess. Many of these lesions have fairly characteristic locations and imaging features. Knowledge of these variants and lesions is essential for accurate diagnosis and to avoid mistaking them for aggressive soft tissue lesions, including sarcomas. Ultrasonography and magnetic resonance imaging are the most useful imaging modalities in evaluating these Benign cystic lesions. Ultrasonography can distinguish cysts from solid lesions and assess the degree of vascularity within the lesion. Magnetic resonance imaging can help to delineate the location of the lesion in relation to anatomic structures and also determine if the lesion is cystic or solid when contrast is administered.

Official Title
-----------------
Ultrasound Evaluation of Cysts and Cyst-like Lesions in and Around the Knee:In Comparison to Magnetic Resonance Imaging

Conditions
-----------------
Knee Cyst Popliteal (___Cm)

Intervention / Treatment
-----------------
* Radiation: Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. clinically diagnosed cystic lesions in and around the knee. Exclusion Criteria: arthroscopy or surgical intervention to the knee joint. fracture repaired by metal plates or screws. claustrophobia. contraindications to MRI as patients with implanted pacemaker or defibrillator, ferromagnetic aneurysm clips and metallic foreign body at the knee joint.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: Ultrasound|role of ultrasound in comparison to magnetic resonance imaging in diagnosis of benign cystic lesions of knee|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Role of ultrasound and magnetic resonance imaging in diagnosis of Benign knee cysts | Results of ultrasound in comparison to results of magnetic resonance imaging in diagnosis of Benign knee cysts. | within 3 hours |
Measurement of Spinal Kinematics During Various Movements

Study Overview
=================
Brief Summary
-----------------
Participants will perform movements while receiving different visual cues. Spinal kinematics will be measured during these movements and compared between asymptomatic and CLBP participants. Participants will come for a unique session.

Official Title
-----------------
Differences in Spinal Kinematics During Various Activities Between Asymptomatic Subjects and Patients With Chronic Low Back Pain

Conditions
-----------------
Low Back Pain

Intervention / Treatment
-----------------
* Other: Visual cues


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - sufficient French level to understand the instructions for the tests, the information sheet, the consent form. For CLBP patients: - diagnosis of non-specific low back pain (pain from lower ribs to gluteal folds) for more than 3 months. For asymptomatic participants: no history of LBP requiring medical attention during the last two years no other concomitant pain or condition that could compromise the evaluation of lumbar kinematics. Exclusion Criteria: pregnancy skin allergy to tape body mass index (BMI) above 32 For patients with CLBP only: specific low back pain (such as the presence of infection, rheumatological or neurological diseases, spinal fractures, tumours) any known important spinal deformities previous back surgery that limits spinal mobility high level of pain at the time of experiment that prevents repeated movements (severity and irritability) other concomitant pain or condition that could compromise the evaluation of spinal kinematics.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic low back pain (CLBP)<br>All CLBP patients should present with non-specific low back pain (pain from lower ribs to gluteal folds) for more than 3 months. | Other: Visual cues<br>* Participants will be asked to move following cues displayed on a screen in front of them.<br>|
| Asymptomatic controls<br>Asymptomatic participants should have had no history of LBP requiring medical attention during the last two years and no other concomitant pain or condition that could compromise the evaluation of lumbar kinematics. | Other: Visual cues<br>* Participants will be asked to move following cues displayed on a screen in front of them.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Spinal kinematics | Spinal kinematics will be measured at the lumbar and thoracic spine in degrees | Day 1 |
Pigtail Catheter for Drainage of (Pneumothorax/Simple Effusion) is a Effective Procedure

Study Overview
=================
Brief Summary
-----------------
Assessment and evaluation of Pigtail application in drainage of pneumothorax and haemothorax.

Detailed Description
-----------------
Chest injuries are common following blunt and penetrating trauma. Fewer than 10 per cent of blunt injuries and 15-30 per cent of penetrating injuries require surgical management1. Most can be managed with tube thoracostomy to expand the lung (pneumothorax) or to drain blood (haemothorax)2. Although tube thoracostomy is fairly effective, it can be associated with complications such as mispositioning, malfunction, or injury by insertion through the diaphragm or liver3-5. The standard tube size. Has usuallybeen32-40Fr.Insertion of such a large -calibre tube requires a cut-down technique, can be traumatic, and is often associated with signiﬁcant pain and discomfort. Pigtail catheters, originally used by cardiologists to drain chronic pericardial effusion6, were later modiﬁed and adapted for pleural drainage7. Because of their small size and reduced trauma during placement, patients may experience signiﬁcantly decreased pain and discomfort. Pigtail catheters are frequently used in the paediatric population8-10, as well as in adult, non-traumatic situations11-17 Pigtail catheters inserted at the bedside have similar efﬁcacy to traditional chest tube.

Official Title
-----------------
Pigtail Catheter for Drainage of (Pneumothorax/Simple Effusion) is a Effective Procedure

Conditions
-----------------
Pleural Effusion

Intervention / Treatment
-----------------
* Device: pigtail


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: iatrogenic pneumothorax Exclusion Criteria: Age less than 18 years. refused to participate. Unconscious. spontaneous pneumothorax.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: pigtail|pigtail catheter insertion in chest in the pleural cavity|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effective drainage of pleural effusion and pneumothorax | Effective drainage of pleural effusion and pneumothorax by using the imaging Rhea's method . techniques (chest x-ray and ultrasound ) By measuring the pneumothorax rim and pleural effusion in centimeters . Sum of interpleural distance Read pneumothorax size from table PA and AP . | baseline |
Environmental Health and Myopia Prevention and Control

Study Overview
=================
Brief Summary
-----------------
Myopia is one of the major causes of low visual acuity during childhood. It is generally more prevalent in urban areas than in rural areas. Current evidence does not address our understanding of the myopia incidence and development and associated risk geographic factors, such as green spaces. Therefore, our study aimed to evaluate the association between geographic factors and myopia base on a population-based large-scaled cohort design.

Official Title
-----------------
Environmental Health and Myopia Prevention and Control: A Longitudinal Study in China

Conditions
-----------------
Refractive Errors, Myopia (Disorder)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: schoolchildren in the 1st to 4th grades Exclusion Criteria: schoolchildren unwilling to participate

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the changes of spherical equivalent refractive (RSE) | A multi-linear regression was used. | up to 3 years |